Source-backed
Understand why undetectable HBV DNA does not automatically mean treatment can stop, and what to ask your doctor.
After taking antiviral medicine for a while, you may feel relieved to see “HBV DNA not detected” on your report. A natural question follows: if the virus cannot be detected, can I stop treatment?
For someone receiving antiviral treatment for chronic hepatitis B, one undetectable HBV DNA result is not enough to decide that treatment can stop. Other markers, liver health, and results over time also matter. China chronic hepatitis B guideline, 2022
No viral DNA was detected in that blood sample; this does not prove that HBV has been completely eliminated. “Below the quantification limit” is different: a report saying “<15 IU/mL, detected” means viral DNA was found, but could not be measured accurately. Read the full report. CDC laboratory guidance
HBV DNA measures circulating viral replication. Hepatitis B surface antigen, or HBsAg, is a separate marker: undetectable DNA does not automatically mean HBsAg has disappeared.
Functional cure generally includes sustained HBsAg loss and undetectable HBV DNA after treatment ends. Viral genetic material may still remain in liver cells. Viral suppression, surface antigen loss, and complete viral elimination are different outcomes. China guideline: definitions
Medicines such as entecavir and tenofovir suppress viral replication, slow cirrhosis progression, reduce liver cancer risk, and improve long-term survival. Better results can mean treatment is working. WHO notes that most people who start chronic hepatitis B treatment need to continue it for life. WHO hepatitis B fact sheet
Some carefully selected patients can. Guidelines differ; clinicians assess cirrhosis, HBeAg and HBsAg status, duration of viral suppression, and reliable follow-up. People with cirrhosis should be particularly cautious. Stopping can cause viral rebound, hepatitis flares, and sometimes liver decompensation. Any stopping plan must include monitoring and criteria for restarting treatment. EASL 2025 hepatitis B guideline
Continue your current prescription and bring previous reports. Ask your doctor:
An undetectable result is encouraging. Work with your doctor to maintain the benefit you have achieved.
This article provides education about oral antiviral treatment for chronic hepatitis B, not an individual instruction to stop medicine. Preventive treatment during pregnancy or immunosuppression requires a separate assessment.
Treatment
Supports the benefits of entecavir and tenofovir and the need for long-term treatment for most patients.
Interpreting Hepatitis B Laboratory Results
Supports the distinction between undetectable HBV DNA and detectable DNA below the quantification limit; this surveillance source is not used to set treatment stopping criteria.
Definitions and nucleos(t)ide analogue treatment duration
Supports functional cure terminology and the need to consider more than a single HBV DNA result before stopping treatment.
Stopping nucleos(t)ide analogue therapy
Supports clinician selection, close follow-up, retreatment planning, and the risks of relapse and decompensation after discontinuation.
A practical guide for people told they have cirrhosis or advanced fibrosis: antiviral care, cancer surveillance, varices, ascites, medicine safety, nutrition, and emergency signs.
A visit-preparation checklist for chronic hepatitis B care, including HBV DNA, ALT, liver cancer surveillance, medicine adherence, and questions to ask.
What HBV reactivation means, which treatments should trigger screening, and what to ask before cancer or immune-suppressing therapy starts.